2024
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
D’Onofrio G, Herring A, Perrone J, Hawk K, Samuels E, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall M, Walsh S, Dziura J, Fiellin D. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Network Open 2024, 7: e2420702. PMID: 38976265, PMCID: PMC11231806, DOI: 10.1001/jamanetworkopen.2024.20702.Peer-Reviewed Original ResearchConceptsClinical Opiate Withdrawal ScaleExtended-release buprenorphineOpioid use disorderPrecipitated withdrawalOpioid withdrawalOpioid use disorder treatmentCow scoreClinical Opiate Withdrawal Scale scoreAdverse eventsNonrandomized trialsSevere opioid use disorderDays of opioid useOpiate Withdrawal ScaleModerate to severe opioid use disorderFormulation of buprenorphineOpioid use disorder careWithdrawal ScaleUse disorderAssociated with medicationsNonprescribed opioidsPain scoresExtended-releaseInjection painOpioid useAdult patients
2022
Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics
Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics. JAMA Network Open 2022, 5: e2236904. PMID: 36251291, PMCID: PMC9577676, DOI: 10.1001/jamanetworkopen.2022.36904.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismAnalgesics, OpioidFemaleHIV InfectionsHumansMaleMiddle AgedOpioid-Related DisordersTobacco Use DisorderConceptsTobacco use disorderHIV clinicOpioid use disorderUse disordersAlcohol use disorderAddiction treatmentControl periodImplementation facilitationAdoption of medicationsMulticomponent implementation strategyProvision of MOUDUS HIV clinicsMaintenance periodElectronic health record dataHealth record dataEvaluation periodAdult patientsMean ageClinical trialsMAIN OUTCOMEClinicMOUDPatientsDisordersPatient incentives
2021
High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
Herring AA, Vosooghi AA, Luftig J, Anderson ES, Zhao X, Dziura J, Hawk KF, McCormack RP, Saxon A, D’Onofrio G. High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Network Open 2021, 4: e2117128. PMID: 34264326, PMCID: PMC8283555, DOI: 10.1001/jamanetworkopen.2021.17128.Peer-Reviewed Original ResearchConceptsOpioid use disorderEmergency departmentBuprenorphine inductionRespiratory depressionAdverse eventsUse disordersUntreated opioid use disorderSerious adverse eventsFurther prospective investigationLength of stayUrban emergency departmentSafety-net hospitalAdvanced practice practitionersElectronic health recordsUnique cliniciansSublingual buprenorphineBuprenorphine doseED visitsED encountersCase seriesED patientsED physiciansSupplemental oxygenMedian lengthUnique patients
2020
All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors
Gordon K, Manhapra A, Crystal S, Dziura J, Edelman E, Skanderson M, Kerns R, Justice A, Tate J, Becker W. All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors. Drug And Alcohol Dependence 2020, 216: 108291. PMID: 33011662, PMCID: PMC7644145, DOI: 10.1016/j.drugalcdep.2020.108291.Peer-Reviewed Original ResearchConceptsMorphine equivalent daily doseCause mortalityLong-term opioid therapyTime-updated Cox regressionStrong dose-response relationshipUnnatural deathsEquivalent daily doseDose-response relationshipOpioid doseOpioid therapyUninfected patientsOpioid useDaily doseCox regressionMortality outcomesTherapy doseHigh doseMale veteransOverdose fatalitiesOverdose mortalityPLWHMortalityHIVPatientsDoseAssociation of prescription opioids and incident cardiovascular risk factors among post-9/11 Veterans
Chui PW, Gordon KS, Dziura J, Burg MM, Brandt CA, Sico JJ, Leapman MS, Cavanagh CE, Rosman L, Haskell S, Becker WC, Bastian LA. Association of prescription opioids and incident cardiovascular risk factors among post-9/11 Veterans. Preventive Medicine 2020, 134: 106036. PMID: 32097753, DOI: 10.1016/j.ypmed.2020.106036.Peer-Reviewed Original ResearchConceptsCVD risk factorsLong-term opioid therapyCurrent smoking statusRisk factorsOpioid useOpioid therapySmoking statusCardiovascular diseaseHigh riskLong-term exposureIncident cardiovascular risk factorsModifiable CVD risk factorsPrevalent CVD risk factorsFirst primary care visitCardiovascular risk factorsPrimary care visitsBaseline periodElectronic health record dataMain outcome measuresHealth record dataOpioid prescriptionsCare visitsPrescription opioidsMain exposureOutcome measures
2015
Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV
Becker WC, Gordon K, Jennifer Edelman E, Kerns RD, Crystal S, Dziura JD, Fiellin LE, Gordon AJ, Goulet JL, Justice AC, Fiellin DA. Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV. AIDS And Behavior 2015, 20: 679-686. PMID: 26384973, PMCID: PMC5006945, DOI: 10.1007/s10461-015-1197-5.Peer-Reviewed Original Research
2014
Using Multiple Daily Pain Ratings to Improve Reliability and Assay Sensitivity: How Many Is Enough?
Heapy A, Dziura J, Buta E, Goulet J, Kulas JF, Kerns RD. Using Multiple Daily Pain Ratings to Improve Reliability and Assay Sensitivity: How Many Is Enough? Journal Of Pain 2014, 15: 1360-1365. PMID: 25283469, DOI: 10.1016/j.jpain.2014.09.012.Peer-Reviewed Original ResearchConceptsPain intensity ratingsPain treatment trialsPain ratingsTreatment trialsIntensity ratingsDaily pain ratingsMedical Center patientsIMMPACT recommendationsBaseline measurement periodCenter patientsPain assessmentBland-Altman analysisClinical trialsSecondary data analysisDaily callsDaily ratingsTrialsMeaningful differencesAssay sensitivityMeasure reliabilityAdequate reliabilitySpecific recommendationsPatientsSmall subsetBaseline